{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:13:59Z","timestamp":1789611239403,"version":"build-2803163510"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cefiderocol is a novel catechol siderophore cephalosporin antibiotic developed to treat resistant gram-negative infections. We describe its successful use as rescue therapy, combined with surgical debridement, to treat a patient with osteomyelitis due to extensively drug-resistant Acinetobacter baumannii. Bacterial whole-genome sequencing identified the strain and antibiotic resistance determinants.<\/jats:p>","DOI":"10.1093\/ofid\/ofaa150","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:50:57Z","timestamp":1588726257000},"source":"Crossref","is-referenced-by-count":37,"title":["Case Report: Successful Rescue Therapy of Extensively Drug-Resistant Acinetobacter baumannii Osteomyelitis With Cefiderocol"],"prefix":"10.1093","volume":"7","author":[{"given":"Michael","family":"Dagher","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Ruffin","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Marshall","sequence":"first","affiliation":[{"name":"Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA"},{"name":"Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"Departments of Pharmacology, Molecular Biology and Microbiology, Biochemistry, and Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"United States of America CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Taracila","sequence":"first","affiliation":[{"name":"Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA"},{"name":"Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"Departments of Pharmacology, Molecular Biology and Microbiology, Biochemistry, and Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"United States of America CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Bonomo","sequence":"first","affiliation":[{"name":"Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA"},{"name":"Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"Departments of Pharmacology, Molecular Biology and Microbiology, Biochemistry, and Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"United States of America CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Reilly","sequence":"first","affiliation":[{"name":"Department of Orthopedic Surgery, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Vance G","family":"Fowler","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T","family":"Thaden","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"2020052709095773900_CIT0001","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa","volume":"60","author":"Ito","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020052709095773900_CIT0002","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s10096-017-3063-z","article-title":"Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant gram-negative pathogens","volume":"36","author":"Dobias","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020052709095773900_CIT0003","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1093\/jac\/dkz318","article-title":"Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report","volume":"74","author":"Trecarichi","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020052709095773900_CIT0004","volume-title":"Highlights of Prescribing Information: Fetroja (Cefiderocol)","author":"US Food and Drug Administration.","year":"2019"},{"key":"2020052709095773900_CIT0005","doi-asserted-by":"crossref","first-page":"D535","DOI":"10.1093\/nar\/gkw1017","article-title":"Improvements to PATRIC, the all-bacterial bioinformatics database and analysis resource center","volume":"45","author":"Wattam","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2020052709095773900_CIT0006","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1093\/jac\/dks261","article-title":"Identification of acquired antimicrobial resistance genes","volume":"67","author":"Zankari","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2020052709095773900_CIT0007","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1128\/CMR.00117-13","article-title":"OXA \u03b2-lactamases","volume":"27","author":"Evans","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2020052709095773900_CIT0008","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.chembiol.2013.07.015","article-title":"Structural basis for carbapenemase activity of the OXA-23 \u03b2-lactamase from Acinetobacter baumannii","volume":"20","author":"Smith","year":"2013","journal-title":"Chem Biol"},{"key":"2020052709095773900_CIT0009","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/j.ijid.2010.02.1582","article-title":"Outbreak of (OXA-66 carbapenemase) multidrug-resistant Acinetobacter baumannii in a Spanish tertiary-care hospital: epidemiology and study of patient movements","volume":"14","author":"Gonzalez","year":"2010","journal-title":"Int J Infect Dis"},{"key":"2020052709095773900_CIT0010","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1128\/AAC.01512-06","article-title":"An OXA-66\/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii","volume":"51","author":"Hu","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2020052709095773900_CIT0011","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/jac\/dks382","article-title":"Conversion of OXA-66 into OXA-82 in clinical Acinetobacter baumannii isolates and association with altered carbapenem susceptibility","volume":"68","author":"Zander","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2020052709095773900_CIT0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01872-19","article-title":"Long-term compassionate use of cefiderocol to treat chronic osteomyelitis caused by extensively drug-resistant pseudomonas aeruginosa and extended-spectrum-beta-lactate-producing klebsiella pneumoniae in a pediatric patient. Antimicrob Agents Chemother","author":"Alamarat","year":"2020"},{"key":"2020052709095773900_CIT0013","volume-title":"Antimicrobial Drugs Advisory Committee: Cefiderocol Briefing Document (NDA#209445). Florham Park, NJ: Shionogi Inc","author":"Shionogi Inc.","year":"2019"},{"key":"2020052709095773900_CIT0014","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ejmech.2018.06.014","article-title":"Cefiderocol (S-649266), a new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship","volume":"155","author":"Aoki","year":"2018","journal-title":"Eur J Med Chem"},{"key":"2020052709095773900_CIT0015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12275-018-8114-3","article-title":"Interdependence between iron acquisition and biofilm formation in Pseudomonas aeruginosa","volume":"56","author":"Kang","year":"2018","journal-title":"J Microbiol"},{"key":"2020052709095773900_CIT0016","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/cid\/ciy963","article-title":"Compassionate use of cefiderocol as adjunctive treatment of native aortic valve endocarditis due to extremely drug-resistant Pseudomonas aeruginosa","volume":"68","author":"Edgeworth","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020052709095773900_CIT0017","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","article-title":"Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins","volume":"22","author":"Craig","year":"1995","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020052709095773900_CIT0018","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2020052709095773900_CIT0019"},{"key":"2020052709095773900_CIT0020","doi-asserted-by":"crossref","first-page":"D566","DOI":"10.1093\/nar\/gkw1004","article-title":"CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database","volume":"45","author":"Jia","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2020052709095773900_CIT0021","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1128\/AAC.01897-13","article-title":"Antimicrobial resistance determinants in Acinetobacter baumannii isolates taken from military treatment facilities","volume":"58","author":"Taitt","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020052709095773900_CIT0022","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fmicb.2011.00203","article-title":"Acquired antibiotic resistance genes: an overview","volume":"2","author":"van Hoek","year":"2011","journal-title":"Front Microbiol"},{"key":"2020052709095773900_CIT0023","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jgar.2017.09.016","article-title":"Phenotypic and genotypic detection of \u03b2-lactamases in Acinetobacter spp. isolates recovered from Lebanese patients over a 1-year period","volume":"12","author":"Hajjar Soudeiha","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"2020052709095773900_CIT0024","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1128\/AAC.49.7.2941-2948.2005","article-title":"Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C enzymes","volume":"49","author":"Hujer","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2020052709095773900_CIT0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0378-1097(03)00123-X","article-title":"A novel sequence framework (bla(TEM-1G)) encoding the parental TEM-1 beta-lactamase","volume":"220","author":"Pomba-F\u00e9ria","year":"2003","journal-title":"FEMS Microbiol Lett"},{"key":"2020052709095773900_CIT0026","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.eimc.2019.06.009","article-title":"Evolution of the antimicrobial resistance rates in clinical isolates of Pseudomonas aeruginosa causing invasive infections in the south of Spain","volume":"38","author":"Fern\u00e1ndez-Cuenca","year":"2020","journal-title":"Enferm Infecc Microbiol Clin"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa150\/33172938\/ofaa150.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/5\/ofaa150\/33315060\/ofaa150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/5\/ofaa150\/33315060\/ofaa150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T04:24:07Z","timestamp":1666499047000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa150\/5829900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa150","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,5,1]]},"article-number":"ofaa150"}}